RINVOQ Advances to Phase 3 Clinical Trials for Lupus Treatment
AbbVie announced that its drug therapy upadacitinib (also known as RINVOQ®) is entering Phase 3 clinical trial for treatment of lupus. RINVOQ is already approved for the treatment of other autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, and eczema.
In the M19-130 Phase 2 trial of RINVOQ, the drug met its primary endpoint either given alone or as a combination therapy to people with moderately or severely active lupus disease. The drug was given to five groups, a total of 341 people, and none of the trial participants exhibited any new safety issues with the treatment.
Continue to follow the Lupus Foundation of America for updates on RINVOQ as well as other lupus clinical trials.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.